Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.


CSE:AGN - Post by User

Comment by Closure70on Mar 31, 2021 2:42pm
184 Views
Post# 32915776

RE:Topline data

RE:Topline dataRepoirting in both Canada and US that hospitalization is up, ICU's are jammed...with variants and third waves happening at the same time as vaccinations, think there is still a significant play for AGN within this direction.  The IB shot themselves in the foot with the immeiate downgrade, think they are shaking the tree a bit to free up some cheap shares.  Time will tell..along with what will be the next phase of discusions with the FDA - Emergency use.

Not to mention that lung scaring hasn't been accounted for as of yet, wich would probably be within their next stage of discussions with the FDA.

Agree that management should defintely augment their team with some heavy hitters to realize the potential.  As for the Canadian landscape, as announced today, money will immediately be hitting what they think would make the biggest media splash - vaccine manufacturing in this country....
<< Previous
Bullboard Posts
Next >>